SAB Biotherapeutics Inc (SABS) — Cash Flow Reinvestment Rate
SAB Biotherapeutics Inc (SABS) has a Cash Flow Reinvestment Rate of 41.94x as of December 2022, reinvesting $9.09 Million (capex $117.75K plus investments $-8.97 Million) from operating cash flow of $216.72K. Check SAB Biotherapeutics Inc (SABS) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
SAB Biotherapeutics Inc Cash Flow Reinvestment Rate (2020–2021)
Historical reinvestment intensity for SAB Biotherapeutics Inc across 2 annual periods. Explore SABS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for SAB Biotherapeutics Inc (2020–2021)
Year-by-year capital reinvestment analysis for SAB Biotherapeutics Inc. For live market cap and broader valuation context, see SABS market cap overview.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 11.02x | $21.89 Million | $1.99 Million | $10.94 Million | ▲ +333.0% |
| 2020 | 2.54x | $25.45 Million | $10.00 Million | $12.73 Million | — |